NCT01829919View on ClinicalTrials.gov

Pharmacokinetic Evaluation of Brisdelle™ (Formerly Known as Mesafem) Following Single & Repeat Oral Administration in Healthy Postmenopausal Women

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions

Postmenopausal Symptoms

Interventions

DRUG

Brisdelle (paroxetine mesylate)

All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.

Trial Locations (1)

21201

SNBL Clinical Pharmacology Center, Baltimore